Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients

(University of Pennsylvania School of Medicine) The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news